


## CLAIMS

## 1. A compound of the Formula I



5

Formula I

wherein:

10 R1 is NHR10, (substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>alkyl)NHR10 or (unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub>cycloalkyl)NHR10;

R10 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkyl(OH), C<sub>1</sub>-C<sub>6</sub>alkylidenyl(OH)R11, or an amino protecting group;

15 R11 is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)C<sub>1</sub>-C<sub>6</sub>alkyl, C(O)O-C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R2 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R4 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, or C<sub>2</sub>-C<sub>6</sub>alkenyl;

20 R5 is hydrogen, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkoxy, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl;

R6 and R7 are independently hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub>alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated or a substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl group which is optionally partly unsaturated;

R8 is hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>alkyl)C<sub>3</sub>-C<sub>8</sub>cycloalkyl, or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl;

5 Q is -S(O)<sub>2</sub>- or -C(O)-;

m is a number selected from 1 or 2;


R3 is substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, or aryl

10 substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group; and R9 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, C<sub>3</sub>-C<sub>8</sub>cycloalkenyl, cyano, optionally substituted aryl, optionally substituted -O-aryl, optionally substituted -N-aryl, optionally substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C<sub>1</sub>-C<sub>6</sub>alkyl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl, wherein K1 is halo or -CF<sub>3</sub>, and K2 is hydrogen, halo or -CF<sub>3</sub>, or K1 and K2 together form a methylenedioxy group; or

15 R3 is optionally substituted aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl; and R9 is aryl substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group, -O-aryl substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group, -N-aryl substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group, or -S-aryl substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group;

20 25 or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1 having Formula II



Formula II

wherein

5        R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in  
 claim 1 or a pharmaceutically acceptable salt or solvate  
 thereof.

3.        A compound according to claim 1 or 2 wherein R3 is  
 10      selected from substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, substituted C<sub>1</sub>-  
           C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub>  
           cycloalkyl; or a pharmaceutically acceptable salt or solvate  
 thereof.

15        4.        A compound according to claim 3 wherein the  
           substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-  
           C<sub>6</sub>alkylaryl group contains an aryl moiety selected from  
           phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl,  
           isoxazolyl and indolyl which is substituted by from one to  
 20      three groups independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, -OC<sub>1</sub>-  
           C<sub>6</sub> alkyl, -OCF<sub>3</sub>, amide, aryl, aryloxy, SO<sub>2</sub>(C<sub>1-6</sub> alkyl),  
           SO<sub>2</sub>CF<sub>3</sub>, NHamide, carboxamide, sulfonamide, NHsulfonamide,  
           imide, hydroxy, carboxy, nitro, halo, tri(chloro or  
           fluoro)methyl, and cyano; or a pharmaceutically acceptable  
 25      salt or solvate thereof.

5. A compound according to any one of claims 1 to 4 wherein R3 is a substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group or a substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkyl aryl group wherein:

the C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group is methyl, ethyl or propyl;


the C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)- C<sub>1</sub>-C<sub>6</sub>alkyl aryl group is a moiety of formula -CH<sub>2</sub>OCH<sub>2</sub>-;

the substituted aryl moiety is 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,4,6-trifluorophenyl, 2,3,4-trifluorophenyl, 2,4,5-trifluorophenyl, 2,3,6-trifluorophenyl, 2,3,5-trifluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,6-dichlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2-chloro-4-fluorophenyl, 2-methylphenyl, 2,6-difluoro-3-methylphenyl, 3,6-difluoro-2-chlorophenyl, 2-fluoro-6-chlorophenyl, 2-fluoro-3-chlorophenyl, 2-fluoro-4-chlorophenyl, 2,6-difluoro-3-chlorophenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 2-trifluoromethylphenyl, 2-fluoro-5-trifluoromethylphenyl, 2-fluoro-3-trifluoromethylphenyl, 2-fluoro-6-trifluoromethylphenyl, 2-chloro-3-trifluoromethylphenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 2-trifluoromethoxyphenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 4-methanesulphonylphenyl, or 2-methylthiazolyl;

or a pharmaceutically acceptable salt or solvate thereof.


30

6. A compound according to any one of claims 1 to 5 wherein R1 is



or a pharmaceutically acceptable salt or solvate thereof.

7. A compound according to any one of claims 1 to 5  
 5 wherein R1 is selected from  $-\text{C}(\text{CH}_2\text{F})_2\text{NH}_2$ ,  $-\text{C}(\text{CH}_2\text{F})(\text{CH}_2\text{CH}_2\text{F})\text{NH}_2$ ,  
 $-\text{C}(\text{CF}_3)(\text{CH}_3)\text{NH}_2$ ,  $-\text{C}(\text{CH}_2\text{CH}_2\text{F})_2\text{NH}_2$ ,  $-\text{C}(\text{CH}_2\text{CH}_3)(\text{CH}_2\text{CF}_3)\text{NH}_2$ ,



or a pharmaceutically acceptable salt or solvate thereof.

10 8. A compound according to any one of claims 1 to 7  
 wherein R6 and R7 are each  $\text{C}_1\text{-C}_3$  alkyl or form a five or six  
 membered carbocyclic ring; or R6 and R7 are independently  
 $\text{C}_1\text{-C}_6$ alkyl or  $\text{C}_2\text{-C}_6$ alkenyl, in which one or both groups are  
 substituted by one, two, or three halo atoms; or R6 is  
 15 hydrogen and R7 is  $\text{C}_1\text{-C}_6$ alkyl,  $\text{C}_2\text{-C}_6$ alkenyl which is  
 substituted by one, two, or three halo atoms; or R6 and R7  
 together with the carbon atom to which they are attached may  
 form a  $\text{C}_3\text{-C}_8$ cycloalkyl group which is optionally partly  
 unsaturated and which is substituted by one, two, or three  
 20 halo atoms;  
 or a pharmaceutically acceptable salt or solvate thereof.

9. A compound according to any one of claims 1 to 8  
 wherein R4 is hydrogen or methyl, or a pharmaceutically  
 25 acceptable salt or solvate thereof.

10. A compound according to any one of claims 1 to 9  
 wherein R5 is hydrogen,  $\text{C}_1\text{-C}_6$ alkyl,  $\text{C}_1\text{-C}_6$ alkoxy,  $\text{C}_1\text{-C}_6$ alkyl

which is substituted by hydroxy or  $C_1$ - $C_6$ alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

5 11. A compound according to any one of claims 1 to 10 wherein R5 is hydrogen, methyl, ethyl, propyl or n-propyl, or a pharmaceutically acceptable salt or solvate thereof.

10 12. A compound according to any one of claims 1 to 11 wherein R8 is hydrogen,  $C_1$ - $C_6$ alkyl,  $(C_1$ - $C_6$ alkyl) $C_3$ - $C_8$ cycloalkyl, benzyl, 1-phenylethyl,  $C_1$ - $C_6$ alkyl which is substituted by hydroxy, methoxy,  $CONH_2$ , or  $CON(CH_3)_2$ , or  $C_1$ - $C_6$ alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms 15 or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt or solvate thereof.

13. A compound according to any one of claims 1 to 12 wherein R8 is hydrogen, methyl, ethyl or benzyl; or a 20 pharmaceutically acceptable salt or solvate thereof.

14. A compound according to any one of claims 1 to 13 wherein R9 is selected from the group consisting of unsubstituted or substituted thieryl, unsubstituted or 25 substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, 30 cyano, methylsulphonyl, phenyl, phenoxy, thieryl, pyridyl, thiazolyl, oxazolyl, nitro,  $CONH_2$ , furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt or solvate thereof.

15. A compound of according to claim 14 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, thiazolyl, pyridyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, oxazolyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 15 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl; or a pharmaceutically acceptable salt or solvate thereof.


20 16. A pharmaceutical formulation comprising one or more compounds according to any one of claims 1 to 15 or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable diluents or carriers therefor.

25


17. A pharmaceutical formulation according to claim 16 wherein the formulation further comprises one or more growth hormone secretagogue compounds and/or a bone-antiresorptive agent.

30

18. A process for producing a compound of Formula I as defined in any one of claims 1 to 15 comprising coupling a compound of Formula XI or XIb




XI



XI b


with a compound of formula XIII




XIII

wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and Q are as defined in any one of claims 1 to 15.

10 19. A process for producing a compound of Formula I as defined in any one of claims 1 to 15 comprising deprotecting a compound of Formula




or



wherein R2, R3, R4, R5, R6, R7, R8, R9, m and Q are as defined in any one of claims 1 to 12, and PG is an amino protecting group.

20. A process for producing a compound of Formula I as defined in any one of claims 1 to 15 comprising coupling a compound of Formula

5



with a compound of formula XIV

10

HOOC-R1

XIV

wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and Q are as defined in any one of claims 1 to 15.

15

21. A compound according to any one of claims 1 to 15 for the treatment of the human or animal body by therapy.

20

22. Use of a compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for the treatment of a physiological condition which may be modulated or ameliorated by an increase in endogenous growth hormone.

25

-185-

23. A method of using a compound of claim 1 or 2 or a pharmaceutically acceptable salt or solvate thereof for the treatment of a physiological condition which may be modulated or ameliorated by an increase in endogenous growth 5 hormone, which method comprises administering to an animal in need of said treatment an effective amount of a compound of formula I.